You are viewing the site in preview mode
Skip to main content
| |
Non-switched patients, n = 71
|
Switched patients, n = 49
| |
|---|
|
Bevacizumab
|
Bevacizumaba
|
Aflibercepta
|
p-value
|
|---|
|
Sex (males), n (%)
|
29 (41)
|
15 (31)
|
15 (31)
|
0.39
|
|
Age at first injection (years), mean ± SD
|
78.3 ± 7.6
|
76.7 ± 8.0
|
78.0 ± 7.9
|
0.51
|
|
Glaucoma, n (%)
|
|
Treated eye
|
3 (4)
|
5 (10)
|
5 (10)
|
0.36
|
|
Fellow eye
|
4 (6)
|
5 (10)
|
5 (10)
|
0.57
|
|
Pseudophakia, n (%)
|
|
Treated eye
|
33 (46)
|
15 (31)
|
23 (47)
|
0.16
|
|
Fellow eye
|
31 (44)
|
17 (35)
|
21 (43)
|
0.58
|
|
Baseline IOP (mmHg), median (Q1; Q3)
|
|
Treated eye
|
13 (12; 16)
|
13 (10; 15)
|
13 (11; 15)
|
0.85
|
|
Fellow eye
|
14 (11; 16)
|
12 (11; 16)
|
14 (10; 17)
|
0.82
|
|
Last IOP (mmHg), median (Q1; Q3)
|
|
Treated eye
|
13 (11; 15)
|
13 (11; 15)
|
12 (10; 14)
|
0.069
|
|
Fellow eye
|
12 (10; 15)
|
14 (10; 17)
|
13 (10; 15)
|
0.26
|
|
Follow-up (days), mean ± SD
|
495.8 ± 245.2
|
494.5 ± 351.4
|
700.2 ± 331.0
|
< 0.001
|
|
No. of injections, median (Q1; Q3)
|
10 (9; 14.5)
|
9 (6; 15)
|
15 (12; 21)
|
< 0.001
|
|
Injection interval (days), median (Q1; Q3)
|
41.7 (34.2; 49.0)
|
36.5 (34.0; 40.3)
|
35.1 (30.4; 55.5)
|
0.008
|
